Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression

Inclusion Criteria: * Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (\>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (\>125 μm), with or without AMD-related pigmentary abnormalities. * Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin. * Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months. Exclusion Criteria: * Any eye with disease that would interfere with the fundus examinations. * Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia. * Surgeries that may interfere with AMD evaluation. * Long-term use of any medications that are associated with retinal or neural toxicities. * History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment. * Intraocular pressure more than 26 mmHg. * Received cataract surgery in 3 months. * Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer. * Other conditions not suitable for the current study.